Home » Topics » Disease categories and therapies » Urology

Urology
RSS

VPA-985: PK/PD of novel aquaretic agent examined in CHF patients

Nov. 25, 1999

Merck's new PDE5 inhibitors useful for impotence, cardiovascular disorders

Nov. 24, 1999

Pfizer's portfolio includes new early-stage compounds for MED

Nov. 23, 1999

Anthranilic acid derivatives from Fujisawa particularly useful for erectile dysfunction

Nov. 22, 1999

Chronic oral treatment with SR-121463 improves water retention in cirrhotic rats

Nov. 16, 1999

VPA-985 as a novel treatment option for hyponatremia in cirrhosis: clinical results

Nov. 15, 1999

Preclinical data reported at ASN support utility of OP-1 in treating renal disease

Nov. 12, 1999

Novel agents for renal diseases with benzimidazole structure

Nov. 11, 1999

NeXstar research leads to identification of new target for treating renal disease

Nov. 11, 1999

P-selectin blocker SKK-60037 may help prevent progressive renal injuries

Nov. 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...